JAK2 V617F mouse models are genetically engineered knock-in strains that faithfully recapitulate human myeloproliferative neoplasms (MPNs), making them a critical platform for evaluating the safety pharmacology of JAK inhibitors and other targeted therapeutics. Safety pharmacology studies in these disease-relevant mice assess potential adverse effects on the central nervous, cardiovascular, and respiratory systems in accordance with ICH S7A and ICH S7B guidelines. This article provides a comprehensive technical overview of study design, sample types, testing items, analytical methods, and practical applications of JAK2 V617F mouse safety pharmacology experiments.
Technical Overview
The JAK2 V617F mutation is a somatic gain-of-function point mutation in exon 14 of the Janus kinase 2 (JAK2) gene, in which a guanine-to-thymine substitution at nucleotide 1849 converts valine to phenylalanine at codon 617. This mutation is detected in approximately 95% of polycythemia vera patients, 50–60% of essential thrombocythemia patients, and roughly 50% of primary myelofibrosis patients. The mutation abolishes auto-inhibitory control of the JH2 pseudokinase domain, producing constitutive JAK-STAT signaling and cytokine-independent proliferation of hematopoietic cells.
JAK2 V617F knock-in mice, in which the mutation is introduced into the endogenous murine Jak2 locus, develop a phenotype closely resembling human MPN, including elevated hematocrit and red cell mass, leukocytosis, thrombocytosis, progressive splenomegaly, extramedullary hematopoiesis, and bone marrow fibrosis. Because disease physiology can substantially alter drug absorption, distribution, metabolism, and pharmacodynamic sensitivity, safety pharmacology evaluation in JAK2 V617F mice provides disease-contextualized safety data that wild-type rodent studies cannot capture.
Safety pharmacology studies in this model are designed to identify undesirable pharmacodynamic properties of test articles—particularly JAK inhibitors such as ruxolitinib, fedratinib, pacritinib, and momelotinib—on vital physiological functions. The core battery follows ICH S7A recommendations covering the central nervous system (CNS), cardiovascular system, and respiratory system, with supplementary evaluations addressing hematologic, immunologic, and organ-specific toxicities relevant to the myeloproliferative disease background.
Testing Samples
Blood and Plasma Samples
Peripheral blood is collected via submandibular, saphenous, or terminal cardiac puncture under appropriate anesthesia. Samples are used for complete blood counts with differential, reticulocyte counts, coagulation panels (PT, aPTT, fibrinogen), and plasma biochemistry. Plasma is also reserved for toxicokinetic analysis to correlate systemic exposure with observed pharmacodynamic and safety findings.
Serum Samples
Serum is harvested for multiplex cytokine and chemokine profiling, inflammatory marker quantification, and complement assessment. These data help characterize immunomodulatory effects of JAK inhibition in both diseased and wild-type animals.
Tissue Samples
- Spleen and liver for weight recording, histopathology, and assessment of extramedullary hematopoiesis
- Bone marrow (femur and sternum) for cellularity, fibrosis grading, and flow cytometric analysis of hematopoietic stem and progenitor populations
- Heart and aorta for cardiovascular histology and molecular markers of cardiac stress
- Lung tissue for respiratory tract histopathology and pulmonary vascular assessment
- Brain and sciatic nerve for neurohistopathology when CNS findings are observed
- Kidney and gastrointestinal tract for systemic toxicity screening
Urine Samples
Metabolic cage or spot urine collections support urinalysis, renal function markers, and elimination profiling of the test article and metabolites.
Testing Items
The testing program combines the ICH S7A core battery with MPN-relevant supplementary endpoints, ensuring comprehensive characterization of both on-target and off-target safety liabilities.
- Central nervous system: functional observation battery (FOB) or Irwin screen, open-field locomotor activity, rotarod motor coordination, grip strength, body temperature, pupillary response, and behavioral scoring
- Cardiovascular system: heart rate, blood pressure (systolic, diastolic, mean arterial), ECG intervals (PR, QRS, QT, QTc correction), arrhythmia monitoring, telemetry in conscious freely moving animals, and cardiac contractility indicators
- Respiratory system: respiratory rate, tidal volume, minute ventilation, airway resistance markers, and oxygen saturation via whole-body plethysmography
- Hematologic safety: erythrocyte parameters, leukocyte subsets, platelet count and function, and bone marrow progenitor colony assays
- Immunologic safety: lymphocyte subset phenotyping, natural killer cell activity, cytokine release profiling, and infection susceptibility indicators
- Renal and hepatic safety: serum chemistry panels including ALT, AST, ALP, bilirubin, BUN, and creatinine
- hERG channel liability: in vitro potassium channel inhibition screening as an adjunct to in vivo QT assessment per ICH S7B
- Toxicokinetics: plasma concentration–time profiles, exposure margins, and dose proportionality analysis
Testing Methods
Studies are typically conducted in adult JAK2 V617F heterozygous mice with age- and sex-matched wild-type littermates as comparators. Animals are randomized into vehicle control and multiple dose groups, commonly following a single-dose escalating design for core battery evaluation, with recovery groups included where appropriate. All procedures are performed under GLP or GLP-like conditions with IACUC-approved protocols.
- Telemetry: implantable transmitter systems continuously record ECG, blood pressure, body temperature, and activity in conscious, unrestrained mice, enabling detection of delayed or transient cardiovascular events
- Whole-body plethysmography: non-invasive measurement of respiratory parameters across the post-dose observation window
- Behavioral assays: standardized Irwin or FOB protocols, automated open-field chambers, accelerating rotarod, and dynamometer-based grip strength measurement
- Flow cytometry: multi-parameter immunophenotyping of peripheral blood, spleen, and bone marrow to quantify lineage populations, stem cells, and progenitor subsets
- Molecular assays: ELISA and multiplex Luminex panels for cytokines, quantitative PCR and Western blotting for JAK-STAT pathway biomarkers (pSTAT3, pSTAT5), and mutation allele burden measurement
- Histopathology: formalin-fixed, paraffin-embedded tissue sections with H&E staining, reticulin and trichrome staining for marrow fibrosis grading, and blinded pathology review
- Bioanalytical methods: LC-MS/MS quantification of plasma drug levels to support toxicokinetic modeling
Data are analyzed using appropriate statistical methods with repeated-measures or mixed-model designs for telemetry and plethysmography time-series data. Benchmark dose modeling and exposure–response analysis are applied when translating findings to clinical risk assessment.
Applications
Safety pharmacology studies in JAK2 V617F mice support multiple stages of therapeutic development and regulatory science.
- JAK inhibitor development: differential safety profiling of selective and non-selective JAK inhibitors, guiding dose selection and therapeutic window estimation before first-in-human trials
- Disease-contextual risk assessment: identification of adverse effects that emerge only in the myeloproliferative disease state, such as exaggerated hematologic suppression or altered cytokine homeostasis
- Cardiotoxicity evaluation: assessment of cardiac conduction and contractility liabilities, an area of historical concern for kinase inhibitors
- Neurotoxicity screening: structured CNS evaluation to detect sensorimotor and behavioral effects, informed by prior clinical observations with agents in this drug class
- Combination therapy safety: evaluation of JAK inhibitors combined with hypomethylating agents, BCL-2 inhibitors, or interferon formulations
- Regulatory submission support: generation of GLP-compliant data packages for IND-enabling programs and post-marketing safety investigations
- Translational biomarker discovery: identification of pharmacodynamic safety biomarkers that can be monitored in subsequent clinical trials
FAQ
Why use JAK2 V617F mice instead of wild-type mice for safety pharmacology?
Wild-type mice cannot reproduce the altered hematopoiesis, splenomegaly, inflammation, and metabolic state of MPN. Testing in the JAK2 V617F background reveals disease-dependent safety liabilities, such as excessive myelosuppression or paradoxical cytokine responses, that would be missed in healthy animals.
Which regulatory guidelines govern these studies?
The core battery design follows ICH S7A for CNS, cardiovascular, and respiratory evaluation, while ICH S7B applies to proarrhythmia risk assessment including QT prolongation and hERG liability testing. GLP compliance is expected for pivotal studies supporting regulatory submissions.
How many dose groups and animals are typically required?
A standard single-dose core battery design uses a vehicle control plus two or three dose levels, with 6–10 animals per sex per group. Doses are selected to span the pharmacologically active range and reach exposures above the intended therapeutic exposure.
What is the typical study duration?
Acute safety pharmacology studies generally run one to several days per dosing phase, including pre-dose baseline characterization and post-dose monitoring up to 24 hours. Supplementary repeat-dose safety components may extend from two to thirteen weeks.
How are QT data interpreted given the high heart rate in mice?
Murine QT intervals require species-appropriate rate correction formulas such as Mitchell or Fridericia-derived corrections. Continuous telemetry with matched baseline data enables each animal to serve as its own control, improving sensitivity for detecting drug-induced repolarization changes.
Can JAK2 V617F mouse data be directly extrapolated to humans?
These data provide strong translational hypotheses and exposure margins but require integration with data from additional species, in vitro human systems, and clinical monitoring plans. Safety margins are calculated relative to projected human exposure at therapeutic doses.